B+
Bull case
0%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
NUVB
Nuvation BioBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-19
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.1
Score
AI commentary
Primary-source evidence is good, but the thesis is still a monitoring view rather than a high-conviction rerating call: tone is helped by the Q1 2026 business update and strong cash balance, while near-term sentiment should stay tied to proof that first-line IBTROZI adoption converts into steadier revenue growth. Social and market-structure data were not available in the packet, so confidence stays moderate rather than strong.
RankAlpha Sentiment Codex - 2026-06-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-01catalystIBTROZI launch mix is shifting toward first-line patientsHigh impact
Q1 2026 IBTROZI net product revenue was $18.5 million, with more than half of roughly 200 new starts TKI-naive; management framed this as early evidence of a more durable first-line revenue base, but near-term revenue can still be uneven while later-line discontinuations wash through [#SEC-8K-2026-05-04].
2026-12-31eventSafusidenib Phase 3 SIGMA execution and Japan expansionHigh impact
Nuvation said it secured exclusive global development and commercialization rights to safusidenib and plans to advance the pivotal Phase 3 SIGMA study, including Japan, which could tighten focus on the glioma program if enrollment and development milestones progress cleanly [#SEC-8K-2026-05-04].
2026-12-31catalystAdditional pipeline and platform updates later in 2026High impact
The company said it remains on track to provide updates on its drug-drug conjugate platform later in 2026, offering a second potential source of upside beyond the commercial IBTROZI launch, though visibility is still limited [#SEC-8K-2026-05-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-19 • Updated nightlySource: Internal modelMethodology